Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

著者: Georgina V. Long, Jason J. Luke, Muhammad A. Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, Peter Mohr, Reinhard Dummer, Jeffrey E. Gershenwald, Charles H. Yoon, Xi Wu, Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Paolo A. Ascierto - The Lancet 2022 被引用: 147